Endarteritis, infective; Aneurysm, mycotic
Ciprofloxacin

Ciprofloxacin

High
Excellent

General Information

Pseudomonal and other gram-negative infections of urinary tract, bone/joint, abdomen and other sites.

Black Box Warning: Fluoroquinolones, including ciprofloxacin, are associated with disabling and potentially irreversible serious adverse reactions, including tendinitis and tendon rupture, peripheral neuropathy, and CNS effects; discontinue and avoid use if adverse reactions occur. Avoid use in patients with known history of myasthenia gravis.

Monitor QTc in patients with increased risk.

Perform culture and susceptibility tests prior to and during therapy.

Monitor renal funcion and signs of hypersensitivity.

  • QTc prolongation
  • Dysglycemia
  • Tendinopathy and rupture
  • GI upset
  • Rash
  • Retinal detachment
  • CNS toxicity including confusion, psychosis
  • Weakness exacerbation in myasthenia gravis
  • CYP1A2 inhibitor - multiple interactions possible
  • QTc prolongation - increased risk with other agents that prolong QTc
  • Divalent & trivalent cations including Al, Ca, Fe, Mg (antacids, dairy products, iron supplements, some enteral feeds) - decreased absorption
  • Cyclosporine - increased levels of cyclosporine
  • Warfarin - increased INR
  • Methadone - lowered seizure threshold

Antimicrobial class: Fluoroquinolone

Pregnancy category: C

Average serum half life: 4 hours

Biliary penetration: Therapeutic

CSF penetration: Moderate

Lung penetration: Therapeutic

Urine penetration: Therapeutic